>
产品中心 >
Small_molecule >
Medchemexpress/Verteporfin(Synonyms: CL 318952)/HY-B0146/10mM*1mL in DMSO
Description | VerteporfinisabenzoporphyrinderivativemonoacidringA,andcaninhibittheactivityofYAP. |
---|---|
InVitro | VerteporfinisspecificallyselectedbyPDX-cellscreening.Theconcentrationstocause50%growthinhibition(GI50)forPhLO,PhLH,andPhLKare228nM,395nM,and538nM,respectively,whereasGI50forALL-1,TCC-Y/sr,andNPhA1are3.93µM,2.11µM,and5.61µM,respectively.GSHsignificantlyreducesthesensitivityof2outof3PDXcellstoverteporfin.VerteporfinreducesthemitochondrialmembranepotentialinPDXcells[1].VerteporfinreducesthePTX-resistanceonHCT-8/TcellsbyinhibitingYAPexpressionandcombinationtherapywithverteporfinandpaclitaxel(PTX)showssynergismoninhibitionofYAPandcytotoxicitytoHCT-8/T[2]. |
InVivo | Verteporfin(10mg/kg,c.s.c.)anddasatinibsignificantlyreducestheleukemiacellratio,andcombinedtherapyfurtherreducedthenumberofleukemiacellsinthespleen[1]. |
ClinicalTrial | ViewMoreCollapse |
References |
|
PreparingStockSolutions |
Pleaserefertothesolubilityinformationtoselecttheappropriatesolvent. | ||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CellAssay [1] | VerteporfinisdissolvedinDMSO. PDXcellsco-culturedwithS17cellsaretreatedwith16combinationsofverteporfin(60nM,120nM,180nM,and240nM)anddasatinib(12nM,24nM,36nM,and48nM).TheviABIlitiesofcellstreatedwitheachcombinationaremeasuredafter48husingFACSAriaflowcytometer.Inordertoestimatedruginteractionbetweenverteporfinanddasatinib,anormalizedisobologramandfractionaffectedcombinationindex(CI)plotaremadeusingCompuSynsoftware.CIvaluesgreaterthan1.0indicatedantagoNISTiceffects,equalto1.0additiveeffects,andbelow1.0synergisticeffects.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. | ||||||||||||||||||||||||||
AnimalAdministration [1] | PhLOcells(1.0×107/mouse)areinjectedintravenouslyinto6-week-oldmaleNOGmice,whicharethentreatedwithvehicle,verteporfin(140mg/kg/day),dasatinib(20mg/kg/day),andacombinationofthesedrugsfromdays22to28.Verteporfinisadministeredbycontinuoussubcutaneousinfusion(c.s.c.)usingAlzetosmoticpumps.Anintraperitonealinjection(i.p.)isperformedfordasatinib.Allmicearesacrificedonday28andthechimerismofleukemiacellsisinvestigatedbyflowcytometerusingananti-humanCD19antibodyandantimouseCD45antibody.BloodconcentrationsofverteporfinarecalculatedbyLCMS-2020.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. References |
|